Although not discussed as often as diabetes, heart disease, or even oncology, chronic obstructive pulmonary disease (COPD) is a significant, challenging disease state for managed care organizations in 2011. According to a study presented at the American Thoracic Society’s 2006 annual meeting, the US medical costs related to COPD are expected to total approximately $832.9 billion between 2006 and 2026.1
According to the latest report released in December 2010 from the Center for National Health Statistics at the US Centers for Disease Control and Prevention, chronic lower respiratory diseases, which include chronic obstructive pulmonary disease (COPD), have replaced stroke as the third leading cause of death in the United States.1,2
The Medical Group Management Association (MGMA) makes a practice of taking the pulse of its members. MGMA’s membership includes 21,500 professional administrators in 13,700 organizations, representing 275,000 physicians, who provide more than 40% of the healthcare services in the United States. The results of several surveys conducted this year reflect providers’ escalating panic over:
Finding ways to care for chronically ill Americans is quickly becoming one of the singular most critical healthcare challenges of our nation. Nearly 1 of 2 Americans has diabetes, heart disease, or another chronic disease.1 Millions more are at risk, and this generation of youngsters may be the first in history to have poorer health at an earlier age and lower levels of longevity than their parents.2
Among a host of investigational drugs for the treatment of cancer featured during the 2010 meeting of the American Society of Clinical Oncology, the following agents were highlighted as showing great promise.
Crizotinib: Although targeting only a small subset of patients with non–small-cell lung cancer (NSCLC), the investigational agent crizotinib—an oral inhibitor of the ALK gene, which is mutated in about 5% of patients with NSCLC—produced unprecedented response rates in a phase 2 study.
Rising costs pose a significant challenge to the US healthcare system. Congress, public and private payers, and other stakeholders have a significant interest in using comparative effectiveness research to control healthcare costs and support value-based purchasing. Policymakers continue to examine the framework for this research at the national level, while commercial payers are already comparing the effectiveness of products. Widespread use of comparative effectiveness data could have profound implications for manufacturers as well as the entire healthcare system.1
The following findings represent survey responses of medical directors and pharmacy directors (N = 57) from 9 national and many regional health plans from around the country. The survey was conducted during the March 2008 Managed Care Network1 meeting in Orlando, Florida. The percentages shown in the figures represent responses provided by between 49 and 52 of the members who replied to the survey. Additional information can be obtained from Xcenda’s 2008 Oncology Report.2
Page 17 of 19
Results 161 - 170 of 188
Results 161 - 170 of 188